TrialThe lancet. Diabetes & endocrinology2019

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.

Ofri Mosenzon et al.PubMed ↗Publisher ↗

No numbers read from the abstract.